REVTx-99
REVTx-99 is a nasal solution for the prevention and/or treatment of respiratory viral infection and chronic nasal congestion.
Sixty seven percent (67%) of subjects in our Phase 1 healthy volunteer study showed a greater than 5-fold increase in IP-10. Three-fold changes in IP-10 have been shown to be protective against influenza and rhinovirus infection in other clinical studies. Additional information can be found in our corporate presentation.
Background REVTx-99a Phase 1 Study Safety and Biomarker Results REVTX-99a Phase 2 Viral Challenge Study
REVTX-99b Phase 1 Allergen Challenge Study
REVTx-99a Phase 1 Study Safety and Biomarker Results
REVTx-99a was evaluated in Phase 1 healthy volunteer study and was shown to be well tolerated. In addition, REVTx-99a significantly increased the levels of key intranasal (localized) biomarkers of interest (e.g. intranasal cytokines) in a dose dependent manner, but had no effect of systemic cytokines (Figure 2). Clinical studies have shown that a 3-fold change in intranasal IP-10 provides protection from infection with influenza or rhinovirus.
Figure 2. Fold-change in Interferon Protein-10 (IP-10) vs baseline.
We believe a 5-fold change in IP-10 will correlate to clinical activity for preventing or shortening the duration of viral infection. A significant number of subjects receiving REVTx-99a achieved a greater than 5-fold change in IP-10 vs those given placebo (Figure 3).
Figure 3. Subjects with >5-fold change in IP-10
